May is Brain Cancer Awareness Month
Brain Cancer
When it comes to diagnosing brain cancer, providing patients with molecular genetic insights paired with histological features is essential. Labcorp Oncology offers a targeted test menu to support you and your brain cancer patients throughout the continuum of care, from diagnosis to treatment selection.
Applications in Neuro-Oncology
Join Shak Ramkissoon, MD, PhD, VP and Medical Lead at Labcorp Oncology, for a video learning series. He explores the world of neuro-oncology and how Labcorp is working towards a clearer path to better outcomes in oncology care.
Labcorp is proud to partner with the American Brain Cancer Association (ABTA)
The mission of the ABTA is to advance the understanding and treatment of brain tumors with the goals of improving, extending and ultimately, saving the lives of those impacted by a brain tumor diagnosis.
Education and support
Molecular Tumor Board: 14-year-old male with pilocytic astrocytoma harboring BRAF V600E mutation
This MTB reviews a case of a 14-year-old male with pilocytic astrocytoma harboring BRAF V600E mutation. Our team has dvelved into patient's clinical history, discussed cancer diagnostics and treatment given to him.
Immune microenvironment of primary versus metastatic melanoma of the brain
Our findings support the need for combination treatments involving immune checkpoint inhibitors and local radiation therapy to enhance immune system activation in patients with melanoma metastatic to the brain.
Diagnostic
Diagnostic
Reveal® SNP Microarray
Cytogenetics Solid Tumor Array for detecting copy number alterations including gains of chromosome 7 and loss of chromosome 10, EGFR amplification, CDKN2A/B deletions
Therapy Selection
Biomarkers and tests for clinical management and treatment decision-making
Therapy Selection
OmniSeq® INSIGHT
A 523 gene comprehensive genomic and immune profiling assay, including MSI, TMB, EGFR amplification, EGFRvIII, and mutations in IDH1/2, BRAF, FGFR, PTERT, TP53 and ATRX, among others